Attaching fatty acid chains to a short fragment of the human antimicrobial peptide LL-37 dramatically enhanced its ability to kill multiple Candida fungal species, including drug-resistant biofilms.
5 of 24Lipidated KR12 derivatives showed high antifungal activity against planktonic Candida cells, with C14-KR12-NH2 also disrupting drug-resistant biofilms
What the researchers found
Five lipidated derivatives of KR12 (C10, C12, C14, 2-butyloctanoic acid, and 4-phenylbenzoic acid variants) showed strong antifungal activity against planktonic Candida cells, and C14-KR12-NH2 additionally disrupted Candida albicans biofilms—a notoriously drug-resistant state.
Why it matters
Candida infections kill hundreds of thousands of immunocompromised patients globally each year, and resistance to available antifungals is rising. Biofilm-forming Candida is particularly lethal and difficult to treat. A short, modifiable human-derived peptide fragment offers a novel, potentially resistance-resistant therapeutic approach.
The numbers in context
- 24 lipopeptide derivatives synthesized from KR12
- 5 highly active against planktonic Candida cells
- C14-KR12-NH2 active against C. albicans biofilms at 24, 48, and 72 hours
- 4 Candida species tested: C. albicans, C. glabrata, C. tropicalis, C. lipolytica
How the study worked
In vitro study synthesizing KR12-NH2 amide and 24 lipidated derivatives via fatty acid substitution; tested against Candida albicans, C. glabrata, C. tropicalis, and C. lipolytica; antifungal activity assessed for planktonic cells and biofilm cultures at 24/48/72 hours.
Who was studied
In vitro study testing 25 peptide compounds against 4 Candida species (C. albicans, C. glabrata, C. tropicalis, C. lipolytica).
What this study cannot tell us
In vitro only—no animal model testing of antifungal efficacy or safety. Cytotoxicity to human cells was not fully characterized for all derivatives. Optimal lipid chain length may vary across Candida species. Biofilm results limited to C. albicans.
How to read the evidence
Rated preliminary: in vitro study with no animal model or clinical validation; promising proof-of-concept but significant development stages remain.
When this study was published
Published in 2025 in Molecules.
The bigger picture
This work is part of a broader effort to develop shorter, cheaper analogs of LL-37 that retain or enhance its antimicrobial properties. Lipidation is emerging as a general strategy for improving peptide potency and membrane disruption against both bacteria and fungi.
Questions still open
- Does C14-KR12-NH2 show acceptable safety in human cell toxicity assays?
- Can lipidated KR12 overcome resistance in clinical Candida isolates from patients?
- Would C14-KR12-NH2 be effective against other fungi like Aspergillus or Cryptococcus?
Common questions
What is LL-37 and why is it used as a starting point for new drugs?
Why are Candida biofilms so hard to treat?
Read the original research
Anticandidal Activity of Lipopeptides Containing an LL-37-Derived Peptide Fragment KR12.
Molecules (Basel, Switzerland), 30(7)
Citation
Paduszynska, Malgorzata Anna; Neubauer, Damian; Kamysz, Wojciech; Kamysz, Elzbieta. (2025). Anticandidal Activity of Lipopeptides Containing an LL-37-Derived Peptide Fragment KR12.. Molecules (Basel, Switzerland), 30(7). https://doi.org/10.3390/molecules30071598